PURPOSE: To report a series of patients with Streptococcus endophthalmitis after injection with intravitreal bevacizumab prepared by the same compounding pharmacy. DESIGN: Noncomparative consecutive case series. METHODS: Medical records and microbiology results of patients who presented with endophthalmitis after injection with intravitreal bevacizumab between July 5 and July 8, 2011, were reviewed. RESULTS: Twelve patients were identified with endophthalmitis, presenting 1 to 6 days after receiving an intravitreal injection of bevacizumab. The injections occurred at 4 different locations in south Florida. All patients received bevacizumab prepared by the same compounding pharmacy. None of the infections originated at the Bascom Palmer Eye Institute, Miami, Florida, although 9 patients presented to its tertiary-care ophthalmic emergency room for treatment, and 3 additional patients were seen in consultation. All patients were treated initially with a vitreous tap and injection; 8 patients subsequently received a vitrectomy. Microbiology cultures for 10 patients were positive for Streptococcus mitis/oralis. Seven unused syringes of bevacizumab prepared by the compounding pharmacy at the same time as those prepared for the affected patients also were positive for S. mitis/oralis. After 4 months of follow-up, all but 1 patient had count fingers or worse visual acuity, and 3 required evisceration or enucleation. Local, state, and federal health department officials have been investigating the source of the contamination. CONCLUSIONS: In this outbreak of endophthalmitis after intravitreal bevacizumab injection, Streptococcus mitis/oralis was cultured from the majority of patients and from all unused syringes. Visual outcomes were generally poor. The most likely cause of this outbreak was contamination during syringe preparation by the compounding pharmacy.
PURPOSE: To report a series of patients with Streptococcus endophthalmitis after injection with intravitreal bevacizumab prepared by the same compounding pharmacy. DESIGN: Noncomparative consecutive case series. METHODS: Medical records and microbiology results of patients who presented with endophthalmitis after injection with intravitreal bevacizumab between July 5 and July 8, 2011, were reviewed. RESULTS: Twelve patients were identified with endophthalmitis, presenting 1 to 6 days after receiving an intravitreal injection of bevacizumab. The injections occurred at 4 different locations in south Florida. All patients received bevacizumab prepared by the same compounding pharmacy. None of the infections originated at the Bascom Palmer Eye Institute, Miami, Florida, although 9 patients presented to its tertiary-care ophthalmic emergency room for treatment, and 3 additional patients were seen in consultation. All patients were treated initially with a vitreous tap and injection; 8 patients subsequently received a vitrectomy. Microbiology cultures for 10 patients were positive for Streptococcus mitis/oralis. Seven unused syringes of bevacizumab prepared by the compounding pharmacy at the same time as those prepared for the affected patients also were positive for S. mitis/oralis. After 4 months of follow-up, all but 1 patient had count fingers or worse visual acuity, and 3 required evisceration or enucleation. Local, state, and federal health department officials have been investigating the source of the contamination. CONCLUSIONS: In this outbreak of endophthalmitis after intravitreal bevacizumab injection, Streptococcus mitis/oralis was cultured from the majority of patients and from all unused syringes. Visual outcomes were generally poor. The most likely cause of this outbreak was contamination during syringe preparation by the compounding pharmacy.
Authors: Ryan M Rich; Philip J Rosenfeld; Carmen A Puliafito; Sander R Dubovy; Janet L Davis; Harry W Flynn; Serafin Gonzalez; William J Feuer; Richard C Lin; Geeta A Lalwani; Jackie K Nguyen; Gaurav Kumar Journal: Retina Date: 2006 May-Jun Impact factor: 4.256
Authors: Daniel F Martin; Maureen G Maguire; Gui-shuang Ying; Juan E Grunwald; Stuart L Fine; Glenn J Jaffe Journal: N Engl J Med Date: 2011-04-28 Impact factor: 91.245
Authors: S H Lee; S J Woo; K H Park; J H Kim; J H Song; K U Park; J W Heo; H G Yu; Y S Yu; H Chung Journal: Eye (Lond) Date: 2009-05-01 Impact factor: 3.775
Authors: John J Miller; Ingrid U Scott; Harry W Flynn; William E Smiddy; Richard P Corey; Darlene Miller Journal: Am J Ophthalmol Date: 2004-08 Impact factor: 5.258
Authors: J C Gines; M M Nentwich; A H Peggy Bedoya; P Cibils; A Esteche; F Laspina; M Samudio; N Fariña; H M de Kaspar Journal: Ophthalmologe Date: 2012-08 Impact factor: 1.059
Authors: Suzann Pershing; Nidhi Talwar; Stephen T Armenti; Joseph Grubbs; Julie M Rosenthal; Vaidehi S Dedania; Joshua D Stein Journal: Am J Ophthalmol Date: 2019-05-15 Impact factor: 5.258
Authors: Ajay E Kuriyan; Kathleen D Weiss; Harry W Flynn; William E Smiddy; Audina M Berrocal; Thomas A Albini; Darlene Miller Journal: Am J Ophthalmol Date: 2014-01-10 Impact factor: 5.258